Dermata Therapeutics Receives FDA Approval for Xyngari Proprietary Name

TipRanksDec 16 09:25 ET

Express News | Dermata Receives Approval From FDA For The Proprietary Name Xyngari For Its Phase 3 Acne Candidate

BenzingaDec 16 09:04 ET

Trending Stocks Today | MEDIROM Healthcare Technologies Soars 97.04% Post-Market

Moomoo NewsDec 6 17:20 ET

Express News | Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"

BenzingaDec 6 15:59 ET

Dermata Therapeutics Completes Enrollment in DMT310 Phase 3 STAR-1 Trial

TipRanksDec 3 09:20 ET

Express News | Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement

BenzingaDec 3 09:06 ET